


12-27-00

Express Mail Mailing Label No. EL327518446US



PATENT
Atty. Docket No. LEX-004

1646
#9/A
Jed
1/11/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APPLICANTS: Gillies

SERIAL NUMBER: 09/292,217

GROUP NUMBER: 1646

JAN 10 2001

FILING DATE: April 15, 1999

EXAMINER: F. Hamud

TECH CENTER 1600/2900

TITLE: ENHANCEMENT OF ANTIBODY-CYTOKINE FUSION
PROTEIN MEDIATED IMMUNE RESPONSE BY CO-
ADMINISTRATION WITH ANGIOGENESIS INHIBITOR

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND RESPONSE

Sir:

In response to the Office action mailed on June 26, 2000, in connection with the above-identified patent application, Applicant submits this Amendment and Response. A petition and appropriate fee for a three month extension of time up to and including December 26, 2000, is submitted herewith.

Claims 1-27 are pending. Claims 1-27 stand rejected. Applicant amends claims 1, 10, 12, 19, 20 and 25. Applicant adds new claims 28-39. Accordingly, after entry of this Amendment, claims 1-39 will be pending for examination.

AMENDMENT

To the Claims

Please amend claims 1, 10, 12, 19, 20 and 25 to read as follows. (A marked up version of the amended claims is attached at the end of this Amendment and Response.)

1. (Amended) A method of inducing a cytotoxic immune response against a preselected cell-type in a mammal, the method comprising:
- administering to the mammal (i) an immunoconjugate comprising an antibody binding site capable of binding the preselected cell-type and a cytokine capable of inducing the cytotoxic immune response against the preselected cell-type, and (ii) an angiogenesis inhibitor.

01/04/2001 MBERHE 00000041 09292217

01 FEB 2001
11 50 00

215.00 CP
51.00 SP

Sub B1